Navigation Links
BioMS Medical Announces 2007 Year End Results
Date:3/18/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, March 18 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis ("MS"), today announced financial and operational results for the year ended December 31, 2007.

"We continue to focus on the worldwide development of MBP8298, our proprietary synthetic peptide drug for the treatment of multiple sclerosis, which is being evaluated in several late-stage trials in the U.S., Canada and across Europe," said Kevin Giese, President and CEO of BioMS Medical. "The magnitude of the partnership we formed with Lilly at the end of 2007 for the global rights to MBP8298 underscores the enormous potential of our drug and is a validation of all the years of hard work performed by our team."

Currently, BioMS is conducting three clinical trials and one open-label follow-on trial for MBP8298:

- MAESTRO-01: A pivotal phase II/III trial in Canada and Western Europe

evaluating MBP8298 for the treatment of secondary progressive MS

("SPMS"). On January 22, 2007, BioMS announced that the trial had

completed full recruitment of 611 patients at 47 trial sites in

10 countries. Patients are administered either MBP8298 or placebo

every six months for a period of two years. To date, there have been

eight positive safety reviews from the Data Safety Monitoring Board

("DSMB"). An interim analysis on the first 200 patients is expected

in mid-2008.

- MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal

trial. Eligible patients who have successfully completed the blinded,

placebo controlled MAESTRO-01 trial may choose to receive MBP8298 on

an un-blinded basis.

- MAESTRO-03: A U.S. pivotal phase III trial evaluating MBP8298 for the

treatment of SPMS. Enrollment for the randomized, double-blind s
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical to present at BIO CEO & Investor Conference
2. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
3. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical to present at BioContact 2007
9. BioMS Medical announces its intention to renew a normal course issuer bid
10. First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies OmniWave(TM) Endovascular System
11. GHI Medical Deploys New Test to Help Determine Hair Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)...  Berg, a biopharmaceutical company committed to uncovering health ... from its trials using its cancer drug BPM 31510 ... triple negative breast cancer, at the 51 st ... (ASCO), May 29 – June 2 in ... one of the first cancer drugs guided in development ...
(Date:6/1/2015)... , June 1, 2015  Albany Molecular ... today that it has signed a collaborative ... co-market their structure-based drug discovery services to ... of the three-year agreement, AMRI gains access ... and capabilities. HarkerBIO,s customers will be able ...
(Date:6/1/2015)... DUBLIN , May 29, 2015 /PRNewswire/ ... announced the addition of the "2015 ... Market" report to their offering. ... tables, and provides a comprehensive analysis of ... dynamics, size, growth, regulatory requirements, technological trends, ...
(Date:6/1/2015)... 29, 2015 Research and Markets ( ... "2015 Strategies in the UK Flow Cytometry ... This report presents a comprehensive analysis of the ... issues pertaining to the French flow cytometry practice, ... and technological trends with significant market impact during ...
Breaking Biology Technology:Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 2AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 3Strategies in the UK Flow Cytometry Market 2015 2
... MONTVALE, N.J., May 13 Synvista Therapeutics,Inc. (Amex: ... a 160-patient Phase 2 study,of alagebrium in patients with ... A.G.E. [Advanced Glycation End Product],Breaker Alagebrium in Diastolic Heart ... the effect of six months,of oral treatment with 400mg ...
... Yields First Milestone, NEW YORK, May 13 ... pre-disease collection, processing and long-term,storage of adult stem cells ... been secured for a new stem cell collection center ... Smith, MD MBA, NeoStem,s Chairman and Chief Executive Officer,commented: ...
... May 13 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... biopharmaceutical company focused on,endocrine therapy and oncology, ... Phase 2 study of subcutaneously,administered LHRH antagonist ... (BPH", has been accepted for publication in ...
Cached Biology Technology:Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 2Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 3Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 4NeoStem to Expand Stem Cell Collection Center Network to Florida 2NeoStem to Expand Stem Cell Collection Center Network to Florida 3AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 2AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 3AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 4AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 5AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 6
(Date:4/27/2015)... , April 27, 2015  For more than ... trade show has been the premier worldwide event for ... 2015 is a must-attend event for any local, national, ... into the emerging commercial markets and current applications of ... innovations of this projected $48 billion industry, and how ...
(Date:4/21/2015)... Canada , April 21, 2015 ... and evolving government policies are boosting access control systems ... According to a recently published report by ... Opportunities, 2020 ", the access control systems market in ... nearly USD1.2 billion by 2020.The access control systems market ...
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... is measured to understand tree health, fluxes in carbon ... of the most essential and widely collected woody plant ... is awkward and time consuming. Scientists have developed a ... safely and accurately. Dendrometer bands are metal straps ...
... (IL-7) is an important immune messenger protein which ensures ... in our body for immune defence. Researchers from ETH ... function: it enhances the drainage function of lymphatic vessels, ... vessels into the body tissue and return it to ...
... an old dog new tricks." Now neuroscientists are beginning to ... neuroscientists have struggled to understand how the microcircuitry of the ... for the old. New findings published in the journal ... Los Angeles and the University of California, Irvine show how ...
Cached Biology News:New technique for measuring tree growth cuts down on research time 2New technique for measuring tree growth cuts down on research time 3New function for a well-known immune messenger molecule 2New function for a well-known immune messenger molecule 3Researchers discover how inhibitory neurons behave during critical periods of learning 2
supplied with 10x reaction buffer...
... from yeast/leuconostoc overproducer ATP: D-hexose ... 2.7.1.1/1.1.1.49. One unit of HK ... D-glucose in 1 min at ... unit of G6P-DH will oxidize ...
Request Info...
... This product is expected to ... mammalian species but has not been ... single precipitin line against partially purified ... to react with all forms of ...
Biology Products: